Opinion|Videos|July 2, 2024
Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- Please outline your general treatment strategy for patients with high-risk CLL. How do recently presented real-world data influence your treatment approach?
Advertisement
Related to this article
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
4
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
5